JP Morgan Chase
ATXI

JP Morgan Chase’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

JP Morgan Chase’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$3 – 7831
2024
Q3 		$3 Hold
1
– – ﹤0.01% 7350
2024
Q2 		$4 Buy
+1
New +$6 ﹤0.01% 7259
2024
Q1 		– Hold
0
– – – 7349
2022
Q3 		– Hold
0
– – – 6937
2022
Q2 		– Hold
0
– – – 6971
2021
Q3 		– Sell
-1
Closed -$2K – 6882
2021
Q2 		$2K Sell
1
-15
-94% -$74K ﹤0.01% 6221
2021
Q1 		$110K Buy
16
+1
+7% +$6.87K ﹤0.01% 5349
2020
Q4 		$101K Buy
15
+11
+275% +$57.7K ﹤0.01% 4992
2020
Q3 		$52K Sell
4
-1
-20% -$12.2K ﹤0.01% 4927
2020
Q2 		$58K Buy
+5
New +$56.4K ﹤0.01% 4790

Other funds holding ATXI

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

JP Morgan Chase's ATXI Position: Q4 2024 in Review

JP Morgan Chase sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2024, closing a stake of 1 share — an estimated $3 sold.

JP Morgan Chase first reported a position in ATXI in Q2 2020 and held it in 7 quarters. The position peaked at $110K in Q1 2021. 7 funds tracked by Wall St. Rank hold ATXI as of Q4 2024.

  • JP Morgan Chase reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 1 Avenue Therapeutics, Inc. Common Stock share in Q4 2024, an estimated $3.
  • JP Morgan Chase first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
  • JP Morgan Chase's Avenue Therapeutics, Inc. Common Stock position peaked at $110K in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.